Trial Profile
A retrospective study to evaluate correlation between expression of angiogenesis markers and clinical outcomes in renal cell carcinoma patients treated with Sunitinib
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Jan 2017
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 20 Jan 2017 New trial record
- 01 Jan 2017 Results published in the Anticancer Research